Palonosetron intravenous - Dr. Reddy

Drug Profile

Palonosetron intravenous - Dr. Reddy

Alternative Names: Palonosetron hydrochloridee intravenous - Dr. Reddy

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr Reddys Laboratories
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting

Most Recent Events

  • 02 Nov 2012 The US FDA issues tentative approval to palonosetron (0.075 mg/1.5mL and 0.25 mg/5mL) injection for Postoperative nausea and vomiting and Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)
  • 03 Jan 2012 Preregistration for Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)
  • 03 Jan 2012 Preregistration for Postoperative nausea and vomiting (Prevention) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top